Kinfo
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc.

ARMPNYSEHealthcare·US · USD
$3.75
-0.05 (-1.32%)
Prices as of November 10, 2026 · market closed

Price

Key statistics

Valuation
Market cap141.29M USD
Enterprise value431.29M USD
Trailing P/E-0.79
Forward P/E-1.86
PEG ratio0.00
Price / sales25.49
Price / book-0.45
Profitability
Gross margin0.00%
Operating margin-410.84%
Profit margin0.00%
Return on assets-25.83%
Return on equity79.51%
Income (TTM)
Revenue5.54M USD
Gross profit-12.05M USD
EBITDA-33.45M USD
Net income-192.18M USD
Diluted EPS-$5.73
Rev. growth (YoY)15.70%
Balance sheet
Total cash23.95M USD
Total debt313.95M USD
Debt / equity-1.01
Current ratio0.11
Book value / share-$6.22
Cash flow (TTM)
Operating cash flow-25.42M USD
Levered free cash flow-27.41M USD
Shares & price
Shares outstanding37.18M
Float11.90M
Held by institutions13.65%
Beta1.63
50-day MA$3.96
200-day MA$6.94
52-week high$14.98
52-week low$2.75
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-12-0.441.20+372.73%2026-07-233.323.52+6.02%2026-05-13-0.38-3.16−731.58%2026-03-24-0.40-1.00−150.00%
About Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. The company’s current work centers on phage-based medicines designed to target specific bacterial pathogens, with programs addressing infections such as Staphylococcus aureus bacteremia and Pseudomonas aeruginosa-related disease. Its platform combines natural and synthetic bacteriophages with proprietary engineering, microbiological surveillance, and drug development capabilities to support product design, manufacturing, and clinical testing. Armata Pharmaceuticals operates as a specialist in infectious disease therapeutics, serving an important role in the broader biopharmaceutical market by advancing alternative approaches to conventional antibiotics.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Deborah L. Birx M.D.
Employees
61
Headquarters
Los Angeles, CA, United States

Frequently asked questions about Armata Pharmaceuticals, Inc.